Martin Nováček

Materials ScienceBiochemistry, Genetics and Molecular BiologyMedicinePhysics and Astronomy

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial”.

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Critical Care(2022)10.1186/s13054-022-04204-9

N/A

2.1DataRank · unranked

94 citations

Bruno François, Marc Bourgeois, Apostolos Komnos, Ricard Ferrer, Galia Rahav +94 more

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Journal of Antimicrobial Chemotherapy(2021)10.1093/jac/dkab494

N/A

0DataRank · unranked

22 citations

Jean‐François Timsit, Marin H. Kollef, Richard G. Wunderink, Nobuaki Shime, Martin Nováček +12 more